Chrysin sensitizes glioblastoma cells and spheroids to temozolomide treatment by reducing EMT and stemness phenotypes, as well as targeting multidrug resistance proteins
These findings suggest that CHR may be a promising adjuvant to TMZ therapy, providing novel insights into overcoming chemoresistance in GB treatment.
Authors
- Yunus Aksüt (ORCID: https://orcid.org/0000-0001-9407-5019)
- Aslıhan Şengelen (ORCID: https://orcid.org/0000-0003-2512-319X)
- Murat Pekmez (ORCID: https://orcid.org/0000-0002-6150-8372)
- İrem Öğütcü (ORCID: https://orcid.org/0000-0001-7721-5542)
- Dudu Melek Gürsoy
- Özge Kuvet
Institutions
- Koç University (TR)
- Istanbul University (TR)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-09-02
- DOI
- https://doi.org/10.3389/fphar.2025.1643186
- Primary Topic
- Drug Transport and Resistance Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bilimsel Araştirma Projeleri Birimi, Istanbul Üniversitesi